Pittsburgh Post-Gazette Feature Article: "West Virginia University partners with California biotech in new drug discovery"

Officials say artificial intelligence could speed up the discovery and commercialization of new therapies

 
IRVINE, CA, USA – January 28, 2025 – Metropolitan Pittsburgh's largest newspaper, the Pittsburgh Post-Gazette, featured GATC Health's partnership with West Virginia University to collaborate on new drug discovery programs.

The article, "West Virginia University partners with California biotech in new drug discovery." highlights the use of GATC's artificial intelligence platform, Multiomics Advanced Technology™ (MAT) to accelerate the discovery and commercialization of new drug candidates.
 

Excerpted from the story:

The partnership will allow WVU researchers to simulate billions of biological interactions, enabling fast, accurate discovery of molecular targets, new drugs and testing at the earliest stages of development. GATC officials say its technology has already contributed to significant discoveries in addiction, brain cancer, diabetes and other diseases.

“This partnership highlights West Virginia University’s dedication to driving innovation and transforming lives through groundbreaking research,” Clay Marsh, physician and Chancellor & Executive Dean for Health Sciences at WVU, said in a prepared statement. “By joining forces with GATC Health and utilizing their cutting edge AI technology, we are empowering our researchers to accelerate the path from academic discovery to life-changing therapies, ensuring WVU remains at the forefront of addressing crucial health care challenges and delivering meaningful outcomes that benefit patients in West Virginia and across the globe.”

Read the full story

About GATC Health
GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach.  The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.